Risk assessment of second primary cancer according to histological subtype of non-Hodgkin lymphoma

References

• Sant M, Minicozzi P, Mounier M, et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol 2014;15:931–942.
   PubMed Web of Science ®Google Scholar
• Bray F, Ren J-S, Masuyer E, et al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013;132:1133–1145.
   PubMed Web of Science ®Google Scholar
• Belot A, Grosclaude P, Bossard N, et al. Cancer incidence and mortality in France over the period 1980–2005. Rev Epidemiol Sante Publique 2008;56:159–175.
   PubMed Web of Science ®Google Scholar
• Brennan P, Scélo G, Hemminki K, et al. Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma. Br J Cancer 2005;93:159–166.
   PubMed Web of Science ®Google Scholar
• Sant M, Allemani C, De Angelis R, et al. Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States. Eur J Cancer 2008;44:579–587.
   PubMed Web of Science ®Google Scholar
• Morton LM, Turner JJ, Cerhan JR, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007;110:695–708.
   PubMed Web of Science ®Google Scholar
• Adamson P, Bray F, Costantini AS, et al. Time trends in the registration of Hodgkin and non-Hodgkin lymphomas in Europe. Eur J Cancer 2007;43:391–401.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027–5033.
   PubMed Web of Science ®Google Scholar
• Wood ME, Vogel V, Ng A, et al. Second malignant neoplasms: assessment and strategies for risk reduction. J Clin Oncol 2012;30: 3734–3745.
   PubMed Web of Science ®Google Scholar
• Hemminki K, Lenner P, Sundquist J, et al. Risk of subsequent solid tumors after non-Hodgkin's lymphoma: effect of diagnostic age and time since diagnosis. J Clin Oncol 2008;26:1850–1857.
   PubMed Web of Science ®Google Scholar
• Sacchi S, Marcheselli L, Bari A, et al. Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study. Haematologica 2008;94:1335–1342.
   Web of Science ®Google Scholar
• Tward JD, Wendland MMM, Shrieve DC, et al. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 2006;107:108–115.
   PubMed Web of Science ®Google Scholar
• Sacchi S, Marcheselli L, Bari A, et al. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica 2008;93:398–404.
   PubMed Web of Science ®Google Scholar
• Pirani M, Marcheselli R, Marcheselli L, et al. Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis. Ann Oncol 2011;22:1845–1858.
   PubMed Web of Science ®Google Scholar
• Monnereau A, Troussard X, Belot A, et al. Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France. Int J Cancer 2013;132:2378–2387.
   PubMed Web of Science ®Google Scholar
• van de Schans SAM, van Steenbergen LN, Coebergh JWW, et al. Actual prognosis during follow-up of survivors of B-cell non-Hodgkin lymphoma in the Netherlands. Haematologica 2014; 99:339–345.
   PubMed Web of Science ®Google Scholar
• Morton LM, Curtis RE, Linet MS, et al. Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol 2010;28: 4935–4944.
   PubMed Web of Science ®Google Scholar
• Jégu J, Colonna M, Daubisse-Marliac L, et al. The effect of patient characteristics on second primary cancer risk in France. BMC Cancer 2014;14:94.
   PubMed Web of Science ®Google Scholar
• Curtis RE, Freedman DM, Ron E, et al. New malignancies among cancer survivors: SEER Cancer Registries, 1973–2000. Bethesda, MD: National Cancer Institute; 2006.
   Google Scholar
• Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996;17:343–346.
   PubMedGoogle Scholar
• Fritz A, Percy C, Lang A, et al. International classification of diseases for oncology, 3rd ed. Geneva: World Health Organization; 2008.
   Google Scholar
• Gavin A, Rous B, Marcos-Gragera R, et al. Towards optimal clinical and epidemiological registration of haematological malignancies: guidelines for recording progressions, transformations and multiple diagnoses. Eur J Cancer 2014 March 12. [Epub ahead of print]
   Web of Science ®Google Scholar
• De Angelis R, Francisci S, Baili P, et al. The EUROCARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis. Eur J Cancer 2009;45: 909–930.
   PubMed Web of Science ®Google Scholar
• Breslow NE, Day NE. Statistical methods in cancer research. Volume II—The design and analysis of cohort studies. IARC Sci Publ 1987;(82):1–406.
   Google Scholar
• Morton LM, Curtis RE, Linet MS, et al. Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol 2010;28:4935–4944.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Reed JC, Kitada S, Kim Y, et al. Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers. Semin Oncol 2002;29(Suppl. 2):10–24.
   PubMed Web of Science ®Google Scholar
• Micallef INM, Lillington DM, Apostolidis J, et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 2000;18: 947–955.
   PubMed Web of Science ®Google Scholar
• Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol 2013;31:301–307.
   PubMed Web of Science ®Google Scholar
• Weber DM, Dimopoulos MA, Delasalle K, et al. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30:243–247.
   PubMed Web of Science ®Google Scholar
• Leleu X, Soumerai J, Roccaro A, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol 2009;27:250–255.
   PubMed Web of Science ®Google Scholar
• Cornet E, Tomowiak C, Tanguy-Schmidt A, et al. Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia. Br J Haematol 2014;166:390–400.
   PubMed Web of Science ®Google Scholar
• Poulain S, Herbaux C, Bertrand E, et al. Genomic studies have identified multiple mechanisms of genetic changes in Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk 2013;13: 202–204.
   PubMed Web of Science ®Google Scholar
• Brennan P, Coates M, Armstrong B, et al. Second primary neoplasms following non-Hodgkin's lymphoma in New South Wales, Australia. Br J Cancer 2000;82:1344–1347.
   PubMed Web of Science ®Google Scholar
• Dong C, Hemminki K. Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958–1996: a search for common mechanisms. Br J Cancer 2001;85: 997–1005.
   PubMed Web of Science ®Google Scholar